Protein Kinase a in Complex with Rho-Kinase Inhibitors Y-27632, Fasudil, and H-1152P: Structural Basis of Selectivity

Structure

Volumn 11, Issue 12, 2003, Pages 1595-1607

  Breitenlechner, Christine ^a   Gaßel, Michael ^b   Hidaka, Hiroyoshi ^d   Kinzel, Volker ^b   Huber, Robert ^a   Engh, Richard A ^a,c   Bossemeyer, Dirk ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d D Western Therapeutics Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; FASUDIL; H 1152P; PROTEIN KINASE INHIBITOR; RHO KINASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION;

EID: 0344234281     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2003.11.002     Document Type: Article

References (31)

1. Akamine P., Madhusudan, Wu J., Xuong N.H., Eyck L.F.T., Taylor S.S. Dynamic features of cAMP-dependent protein kinase revealed by apoenzyme crystal structure. J. Mol. Biol. 327:2003;159-171.
2. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271:1996;20246-20249.
3. Amano M., Fukata Y., Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp. Cell Res. 261:2000;44-51.
4. Battistutta R., Sarno S., De Moliner E., Papinutto E., Zanotti G., Pinna L.A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 275:2000;29618-29622.
5. Bossemeyer D., Engh R.A., Kinzel V., Ponstingl H., Huber R. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 12:1993;849-859.
6. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
7. Engh R.A., Bossemeyer D. The protein kinase activity modulation sites. mechanisms for cellular regulation - targets for therapeutic intervention Adv. Enzyme Regul. 41:2001;121-149.
8. Engh R.A., Bossemeyer D. Structural aspects of protein kinase control. role of conformational flexibility Pharmacol. Ther. 93:2002;99-111.
9. Engh R.A., Girod A., Kinzel V., Huber R., Bossemeyer D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J. Biol. Chem. 271:1996;26157-26164.
10. Fukata Y., Amano M., Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 22:2001;32-39.
11. Gassel M., Breitenlechner C.B., Ruger P., Jucknischke U., Schneider T., Huber R., Bossemeyer D., Engh R.A. Mutants of protein kinase a that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol. 329:2003;1021-1034.
12. Gibbs C.S., Knighton D.R., Sowadski J.M., Taylor S.S., Zoller M.J. Systematic mutational analysis of cAMP-dependent protein kinase identifies unregulated catalytic subunits and defines regions important for the recognition of the regulatory subunit. J. Biol. Chem. 267:1992;4806-4814.
13. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 23:1984;5036-5041.
14. Ikenoya M., Hidaka H., Hosoya T., Suzuki M., Yamamoto N., Sasaki Y. Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J. Neurochem. 81:2002;9-16.
15. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 57:2000;976-983.
16. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5:1999;221-225.
17. Johnson D.A., Akamine P., Radzio-Andzelm E., Madhusudan, Taylor S.S. Dynamics of cAMP-dependent protein kinase. Chem. Reviews. 101:2001;2243-2270.
18. Löfås S., Johnsson B. A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands. J. Chem. Soc. Chem. Commun. 21:1990;1526-1528.
19. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
20. Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. Rho-associated kinase, a novel serine threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J. 15:1996;2208-2216.
21. Narayana N., Diller T.C., Koide K., Bunnage M.E., Nicolaou K.C., Brunton L.L., Xuong N.H., Ten Eyck L.F., Taylor S.S. Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase. Biochemistry. 38:1999;2367-2376.
22. Ono-Saito N., Niki I., Hidaka H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol. Ther. 82:1999;123-131.
23. Orellana S.A., Amieux P.S., Zhao X., McKnight G.S. Mutations in the catalytic subunit of the cAMP-dependent protein kinase interfere with holoenzyme formation without disrupting inhibition by protein kinase inhibitor. J. Biol. Chem. 268:1993;6843-6846.
24. Prade L., Engh R.A., Girod A., Kinzel V., Huber R., Bossemeyer D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure. 5:1997;1627-1637.
25. Sasaki Y., Suzuki M., Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93:2002;225-232.
26. Shimokawa H., Iinuma H., Kishida H., Nakashima M., Kato K. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina. a multicenter study Circulation. 104:2001;2843.
27. Sinnett-Smith J., Lunn J.A., Leopoldt D., Rozengurt E. Y-27632, an inhibitor of Rho-associated kinases, prevents tyrosine phosphorylation of focal adhesion kinase and paxillin induced by bombesin. dissociation from tyrosine phosphorylation of p130(CAS) Exp. Cell Res. 266:2001;292-302.
28. Tanaka H., Ohshima N., Takagi M., Komeima K., Hidaka H. Novel vascular relaxant, Hmn-1152. its molecular mechanism of action Naunyn-Schmied. Arch. Pharmacol. 358:1998;P3740.
29. Trauger J.W., Lin F.F., Turner M.S., Stephens J., LoGrasso P.V. Kinetic mechanism for human Rho-Kinase II (ROCK-II). Biochemistry. 41:2002;8948-8953.
30. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:1997;990-994.
31. Yang J., Cron P., Good V.M., Thompson V., Hemmings B.A., Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9:2002;940-944.